TAUNS Laboratories,Inc. (197A.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

5.9x

EV/EBITDA

13.1x

Market Cap

JPY 52.01B

MomentumView details →

1D Return

−0.99%

YTD Return

−0.98%

RSI (14)

59.1

ValuationView details →

P/E (Fwd)

5.9x

EV/EBITDA

13.1x

Market Cap

JPY 52.01B

RSI (14)

59.1

MomentumView details →

1D Return

−0.99%

YTD Return

−0.98%

ProfitabilityView details →

Gross Margin

85.61%

Net Margin

24.72%

EBITDA Margin

60.18%

ROE (TTM)

21.20%

ROA (TTM)

8.35%

Asset Turnover

0.36x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+1.05%

EPS CAGR 3Y

+7.50%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

1.17x

Current Ratio

1.44x

Quick Ratio

1.16x

Div Yield

2.79%

Div Rate

JPY 28.00

Div Growth 1Y

+0.90%

Financials snapshotView financials →

Revenue (TTM)

14.92B

Net Income (TTM)

3.69B

Op. CF (TTM)

—

Next earningsNov 12, 2026 →

Latest newsMore news →

Towns announced a capital and business alliance with Taiwan's Asia Pathogenomics to collaborate on metagenomic next-generation sequencing for infectious diseases.15d ago

Towns Co., Ltd. obtained manufacturing and marketing approval in July 2026 for the improved antigen test kit 'ImmunoAce SARS-CoV-2/Flu II' for medical institutions, which can detect both COVID-19 and influenza viruses from one nasal sample in about 10 minutes.17d ago

Similar companies

Heartseed Inc.219A.T ASKA Pharmaceutical Holdings Co.,Ltd.4886.T Cuorips Inc.4894.T Fuji Pharma Co.,Ltd.4554.T JCR Pharmaceuticals Co.,Ltd.4552.T SanBio Company Limited4592.T Find similar companies →

Latest newsMore news →

Towns announced a capital and business alliance with Taiwan's Asia Pathogenomics to collaborate on metagenomic next-generation sequencing for infectious diseases.15d ago Towns Co., Ltd. obtained manufacturing and marketing approval in July 2026 for the improved antigen test kit 'ImmunoAce SARS-CoV-2/Flu II' for medical institutions, which can detect both COVID-19 and influenza viruses from one nasal sample in about 10 minutes.17d ago Towns Co., Ltd. announced its full-year results for the fiscal year ended June 2026, with net sales of 14,369 million yen (down 22.9% year-on-year) and operating profit of 4,200 million yen (down 49.2% year-on-year).17d ago